Vai al contenuto principale
xMedica

NCT07780669ClinicalTrials.gov

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-1)

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

Fase 3624 partecipanti ricercati11 centri2 paesi

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-08-21; recorded start 2026-08-27
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 336 other studies in this databaseCounted from the lead sponsor named in the record (GlaxoSmithKline)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 624 participants (target), run at 11 sites, across 2 countries.

How this score is built
  • Enrolment27/40

    624 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration9/10

    Planned over about 43 months

  • Sponsor scale9/10

    GlaxoSmithKline has led 313 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

Patologie

  • Pulmonary Disease, Chronic Obstructive

Idoneità

Idoneità
SessoTutti
Età40 Years – 80 Years
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria: * Male or eligible female participants * Participants with \>=40 to less than or equal to (\<=) 80 years of age. * An eosinophilic phenotype with elevated BEC. * Moderate to very severe COPD with frequent exacerbations. * Participants with elevated COPD assessment test (CAT) score. * Current or former cigarette smokers. * On triple (Inhaled corticosteroid \[ICS\]+ Long-acting muscarinic antagonist \[LAMA\]+ Long-acting beta-agonist \[LABA\]) or dual inhaled COPD therapy, if ICS is considered not appropriate. Exclusion Criteria: * Current or prior physician diagnosis of asthma * Other clinically significant lung disease. * Pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1. * Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure. * Continuous oxygen therapy (more than 16 hours/ day). * Cor pulmonale resulting in right heart failure and severe pulmonary hypertension. * A current malignancy or history of malignant neoplasm within the last 5 years (except definitively treated non-melanoma skin cancer or carcinoma in situ of the uterine cervix). * Myocardial infarction, unstable angina or stroke within 6 months of screening, unstable arrhythmia. * New York Heart Association class III or IV heart failure. * Other significant medical conditions that could impact participants' safety or study outcomes.

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseFase 3
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoQUADRUPLE (4)
Arruolamento624 partecipanti ricercati

Sponsor e collaboratori

  • GlaxoSmithKline Sponsor

Bracci e interventi

  • Participants receiving GSK5784283 plus standard of careEXPERIMENTAL
  • Participants receiving matching placebo plus standard of carePLACEBO_COMPARATOR

Interventi

  • Farmaco GSK5784283

    GSK5784283 will be administered.

  • Farmaco Placebo

    Placebo will be administered.

  • Farmaco Standard of care

    Standard of care will be administered.

Esiti misurati

  1. Esito primario

    Annualized rate of moderate or severe COPD Exacerbations

    Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (that is greater than or equal to \[\>=\] 24 hours) or result in death.

    Orizzonte temporale Up to Week 78

  2. Esito secondario

    Change from Baseline in St. George's respiratory questionnaire (SGRQ) total score

    SGRQ total score will be measured using the SGRQ for COPD (SGRQ-C). The SGRQ-C is a 14-item participant questionnaire, designed to measure health impairment by addressing the frequency of respiratory symptoms (questions 1-7) and the participant's current state (questions 8-14). The total score will be calculated on 0-100 rating scale and scores expressed as a percentage of overall impairment. Higher scores indicate greater impairment of health.

    Orizzonte temporale Baseline (Day 1) and up to Week 52

  3. Esito secondario

    Change from Baseline in pre-Bronchodilator Forced expiratory volume in 1 second (FEV1)

    FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometry.

    Orizzonte temporale Baseline (Day 1) and at Week 52

  4. Esito secondario

    Annualized rate of COPD exacerbations requiring emergency department (ED) visit or hospitalization

    Annualized rate of COPD exacerbations requiring ED visit or hospitalization (For pooled analysis across studies 300629 and 300631) will be assessed.

    Orizzonte temporale Up to Week 78

  5. Esito secondario

    Annualized rate of moderate/severe COPD exacerbations among participants with elevated screening blood eosinophil counts (BEC)

    Annualized rate of moderate/severe COPD exacerbations among participants with elevated screening BEC (For pooled analysis across studies 300629 and 300631) will be assessed.

    Orizzonte temporale Up to Week 78

  6. Esito secondario

    Time to first moderate or severe COPD exacerbation

    Time to first moderate or severe exacerbation (For pooled analysis across studies 300629 and 300631) will be assessed.

    Orizzonte temporale Up to Week 78

Date

Date
Data di inizio27 agosto 2026 (effettiva)
Conclusione primaria20 luglio 2029 (stimata)
Conclusione15 marzo 2030 (stimata)
Prima pubblicazione21 agosto 2026 (effettiva)
Ultimo aggiornamento17 novembre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltanovembre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

11 centri stanno reclutando

Japan

Japan
StrutturaCittàStato o regioneStato
GSK Investigational SiteFukuokaIn reclutamento
GSK Investigational SiteFukuokaIn reclutamento
GSK Investigational SiteIshikawaIn reclutamento
GSK Investigational SiteTokyoIn reclutamento

United States

United States
StrutturaCittàStato o regioneStato
GSK Investigational SiteDerbyKansasIn reclutamento
GSK Investigational SiteDoralFloridaIn reclutamento
GSK Investigational SiteHumbleTexasIn reclutamento
GSK Investigational SiteHuntsvilleTexasIn reclutamento
GSK Investigational SiteLake CharlesLouisianaIn reclutamento
GSK Investigational SiteStaten IslandNew YorkIn reclutamento
GSK Investigational SiteWest JordanUtahIn reclutamento

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 17 novembre 2026

    Centro aggiunto

    2 sites added (11 total)

    911

  2. 12 novembre 2026

    Centro aggiunto

    2 sites added (9 total)

    79

  3. 5 novembre 2026

    Centro aggiunto

    5 sites added (7 total)

    27

  4. 9 settembre 2026

    Stato modificato

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  5. 9 settembre 2026

    Reclutamento aperto

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  6. 9 settembre 2026

    Centro aggiunto

    2 sites added (2 total)

    02